A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy
This study is investigating the long-term safety and effectiveness of vamorolone, a medicine for boys with Duchenne Muscular Dystrophy (DMD). It's designed for boys who have previously received vamorolone through other research studies or special programs that help people access medicines. The main goal is to check for any long-term side effects, particularly focusing on bone health, eyesight, and how puberty develops. Researchers will also look at overall safety and how the medicine affects a boy's ability to move around. It's a way to keep understanding the medicine better over time.
At a glance
What is this study about?
This study is about a medicine called vamorolone, which is used to treat Duchenne Muscular Dystrophy (DMD). DMD is a condition that causes muscles to become weaker over time. This particular study is for boys who have already been taking vamorolone through earlier research studies or special programmes designed to give patients access to new treatments.
The main aim of this study is to carefully check the long-term safety of vamorolone. Doctors want to understand if taking the medicine over many years has any side effects, especially concerning bones (like fractures in the spine) and other important areas such as eyesight (looking for cataracts) and how puberty progresses. They will also keep an eye on overall health and how much the boys can move around.
The information gathered from this study will help doctors and researchers understand much more about vamorolone. It will provide important details about how safe and effective it is over a longer period, helping ensure it's used in the best possible way for boys with DMD.
Key takeaways
- This study is for boys with Duchenne Muscular Dystrophy already taking vamorolone.
- It aims to understand the long-term safety and effects of vamorolone.
- Researchers will monitor bone health, eyesight, and overall development.
- Participation involves continuing vamorolone and regular health check-ups.
- It's a continuation of previous vamorolone treatment under a new protocol.
Who may be eligible?
This study is specifically for boys who have Duchenne Muscular Dystrophy and have already taken part in previous studies or special programmes involving vamorolone. It's important that you are still taking vamorolone when you join this study.
To be considered, you or your parent/guardian must be willing to provide written permission and be able to follow the study's plan, including attending appointments and completing assessments.
You cannot join if you have certain other medical conditions that the study doctor thinks would make it difficult to take part, or if you had to stop taking vamorolone for safety reasons in the past. Also, if you stopped taking vamorolone for six months or longer for reasons not related to safety, you wouldn't be able to join this particular study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you a boy with Duchenne Muscular Dystrophy?
- Have you taken vamorolone in a previous study or special programme?
- Are you currently taking vamorolone?
- Are you and your parents/guardians able to attend study appointments?
- Do you have any other serious medical conditions that might stop you from joining?
What does participation involve?
If you decide to take part in this study, you will continue to receive vamorolone as prescribed. The study involves regular check-ups and assessments to monitor your health and how the medicine is affecting you. These assessments will help doctors keep track of your bones, eyesight, and overall development, as well as your ability to move. The study will continue for as long as needed to gather important long-term safety information about vamorolone, replacing your previous access program.
Potential risks and benefits
Locations (18)
- UZ Gent (Universitair Ziekenhuis Gent)Verified postcodeGhent, Belgium
- UZ Leuven (Universitair Ziekenhuis Leuven)Verified postcodeLeuven, Belgium
- University Hospital BrnoVerified postcodeBrno, Czechia
- Fakultni Nemocnice MotolVerified postcodePrague, Czechia
- Children's Hospital Agia SofiaVerified postcodeAthens, Greece
- Children's Health Ireland at Tallaght, Tallaght University HospitalVerified postcodeDublin, Ireland
- Schneider Children's Medical CenterVerified postcodePetah Tikva, Israel
- Leiden University Medical CenterVerified postcodeLeiden, Netherlands
- Radboud University NijmegenVerified postcodeNijmegen, Netherlands
- Te Wao Nui - Child Health Service, Wellington HospitalVerified postcodeWellington, New Zealand
- Hospital Universitario Puerta de Hierro MajadahondaVerified postcodeMadrid, Spain
- Hospital Universitario y Politecnico de La FeVerified postcodeValencia, Spain
Common questions
What is Duchenne Muscular Dystrophy (DMD)?
DMD is a genetic condition that causes muscles to get weaker over time.
What is vamorolone?
Vamorolone is a medicine used to treat Duchenne Muscular Dystrophy.
Who can take part in this study?
This study is for boys who have DMD and have already been taking vamorolone in other studies or programmes.
What will doctors be checking for?
They will be checking the safety of long-term vamorolone use, especially looking at bones, eyes, and development.
Will I get new medicine in this study?
No, you will continue to take vamorolone, which you are already receiving.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.